CONSOLIDATED STATEMENTS OF CASH FLOWS - Cash and Restricted Cash (Parenthetical) - USD ($) $ in Thousands		1 Months Ended			12 Months Ended
		Feb. 28, 2023	Jan. 31, 2023	Feb. 28, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Feb. 24, 2023	Dec. 31, 2019
Cash and cash equivalents					$ 658,065	$ 634,848	$ 74,417
Restricted cash	[1]				30,237	382,097	16,432
Total cash and cash equivalents and restricted cash shown in our consolidated statements of cash flows					688,302	1,016,945	90,849		$ 52,224
Repayments of borrowings on revolving credit facility					$ 100,000	$ 0	$ 968,000
Subsequent Event
Cash and cash equivalents								$ 413,000
Credit Facility | Unsecured debt
Repayments of borrowings on revolving credit facility				$ 100,000
Credit Facility | Subsequent Event | Unsecured debt
Repayments of borrowings on revolving credit facility		$ 136,373	$ 113,627

[1] As of December 31, 2022 and 2021, restricted cash consists of proceeds from the sale of joint venture interests and proceeds from the sale of properties to joint ventures held as collateral pursuant to the agreement governing our credit facility, or our credit agreement. We may use these funds to pay for approved expenditures in accordance with our credit agreement. In January 2023, we used the remaining restricted cash held as collateral to repay a portion of the $113,627 reduction in commitments under our credit facility. We continue to be required to hold any proceeds from the sale of properties as restricted cash pursuant to the terms of our credit agreement. Restricted cash also consists of amounts escrowed for real estate taxes, insurance and capital expenditures at certain of our mortgaged properties. Prior to the deconsolidation of the joint venture that owns a life science property located in Boston, Massachusetts, or the Seaport JV, restricted cash also consisted of cash held for the operations of this joint venture.